The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Lung Cancer, Esophageal Cancer. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Prospective Observational Study on the Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
Overview
This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.
Primary outcome measures
- Incidence of >=Grade 3 toxicities [Time frame: 2 years]
Secondary outcome measures (2)
- Overall survival [Time frame: 2 years]
- Progression-free survival [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer.
- Planned to undergo definitive chemoradiotherapy ± immunotherapy;
- Males or females aged 18 to 75;
- Able to communicate with medical staff.
Exclusion Criteria: Patients with cognitive impairments.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Sun Yat-sen University — Guangzhou
Identifiers
NCT: NCT06019455 · 2023-FXY-017